F901318 Single Ascending Dose Study in Healthy Male Volunteers
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections.
This study will test it for the first time in man with the objective of assessing its safety,
tolerability and pharmacokinetic profile.